What it's for (Indications)
- Epirubicin is a cytotoxic anthracycline antibiotic primarily indicated for the treatment of breast cancer.
- It is approved for use in adjuvant therapy for patients with evidence of axillary node involvement following resection of primary breast cancer, aiming to reduce the risk of recurrence and improve overall survival.
- Additionally, epirubicin is utilized in the management of metastatic breast cancer, where it can be administered as a single agent or in combination with other antineoplastic drugs to achieve disease control and palliative effects.
- Its utility extends to other malignancies like gastric cancer and ovarian cancer, though breast cancer remains its most established and FDA-approved primary indication, particularly in the adjuvant setting for node-positive disease.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of epirubicin is highly individualized, depending on the specific indication, the patient's body surface area (BSA), concomitant therapies, and hepatic function. For adjuvant breast cancer, a common regimen involves 100 mg/m² administered intravenously on Day 1, repeated every 21 days for 6 cycles, often in combination with cyclophosphamide and fluorouracil (e.g., FEC regimen), or 120 mg/m² every 3-4 weeks. For metastatic breast cancer, typical doses range from 75 mg/m² to 90 mg/m² every 3 weeks, as a single agent or in combination. Dose adjustments are imperative for patients experiencing myelosuppression, significant hepatic impairment (bilirubin 1.2 to 3 mg/dL may require 50% dose reduction; >3 mg/dL, 75% reduction), or other severe toxicities. Cumulative lifetime dose limits must be carefully observed to mitigate the risk of severe cardiotoxicity, generally not exceeding 900-1000 mg/m². |
Safety & Warnings
Common Side Effects
- Epirubicin can induce a range of adverse effects, primarily due to its cytotoxic nature.
- Common side effects include profound myelosuppression (leading to neutropenia, leukopenia, anemia, and thrombocytopenia), nausea, vomiting, mucositis/stomatitis, reversible alopecia (complete hair loss in many patients), diarrhea, anorexia, and asthenia.
- More serious and potentially life-threatening adverse events encompass cardiotoxicity, including acute and chronic forms, which can progress to irreversible congestive heart failure.
- Other significant risks include secondary acute myeloid leukemia (sAML) and myelodysplastic syndrome (MDS), particularly when used in conjunction with other DNA-damaging agents or radiotherapy.
- Extravasation at the injection site can cause severe local tissue necrosis, blistering, and pain.
- Patients may also experience a harmless reddish discoloration of the urine for 1-2 days post-administration due to drug excretion.
- Hypersensitivity reactions, including anaphylaxis, have also been reported, necessitating vigilance during administration.
Serious Warnings
- Black Box Warning: **WARNING: MYELOSUPPRESSION, CARDIOTOXICITY, SECONDARY MALIGNANCIES, AND EXTRAVASATION** **Myelosuppression:** Epirubicin administration results in profound, dose-dependent myelosuppression, primarily leukopenia and neutropenia, which can lead to life-threatening infections, sepsis, and hemorrhagic complications. Frequent monitoring of complete blood counts is essential during therapy, and dosage adjustments or treatment delays may be required based on nadir counts and recovery. **Cardiotoxicity:** Epirubicin can cause irreversible myocardial damage and congestive heart failure (CHF) that can occur during or months to years after treatment. The risk of cardiac toxicity increases with increasing cumulative doses and is significantly heightened in patients with pre-existing cardiac disease, prior mediastinal irradiation, or concomitant use of other cardiotoxic agents. Left ventricular ejection fraction (LVEF) must be assessed before and regularly during treatment to monitor cardiac function. **Secondary Malignancies:** Treatment with epirubicin has been associated with an increased risk of developing secondary acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), particularly when used in combination with other DNA-damaging antineoplastic agents or radiation therapy. These secondary malignancies can manifest several years after initial epirubicin exposure and are often therapy-related. **Extravasation:** Epirubicin is a vesicant, and extravasation during intravenous administration can lead to severe local tissue necrosis, blistering, and pain, potentially requiring surgical intervention including skin grafting. Proper administration technique into a free-flowing intravenous infusion and careful monitoring of the injection site are crucial to minimize this risk, and extravasation should be managed immediately according to established protocols.
- Several critical warnings are associated with epirubicin therapy.
- **Cardiotoxicity** is a major dose-limiting concern; patients require thorough cardiac evaluation, including left ventricular ejection fraction (LVEF) assessment (e.
- g.
- , MUGA scan or echocardiogram), before and during treatment.
- The risk is elevated with pre-existing cardiac disease, prior anthracycline exposure, mediastinal irradiation, or concurrent cardiotoxic drugs.
- **Myelosuppression** is profound and can lead to life-threatening infections or hemorrhage, necessitating frequent complete blood count monitoring and potential dose modifications.
- **Secondary malignancies**, particularly therapy-related AML and MDS, have been observed, emphasizing the need for long-term monitoring.
- **Extravasation** can result in severe tissue damage, requiring careful administration through a free-flowing intravenous infusion and immediate management if it occurs.
- **Hepatic impairment** necessitates dose reduction due to impaired drug clearance and increased toxicity risk.
- Epirubicin is **teratogenic** and must not be used during pregnancy; women of childbearing potential should use effective contraception, and men should be advised on fertility preservation if applicable.
- Live vaccinations are contraindicated due to immunosuppression.
How it Works (Mechanism of Action)
Epirubicin functions as an anthracycline cytotoxic agent, exerting its antineoplastic effects through multiple mechanisms. Its primary mode of action involves intercalation into DNA, leading to the inhibition of topoisomerase II. This crucial enzyme is responsible for regulating DNA supercoiling, and its inhibition by epirubicin results in the accumulation of cleavable complexes that induce DNA strand breaks. These breaks ultimately disrupt DNA replication and transcription, hindering cell proliferation. Additionally, epirubicin generates reactive oxygen species, such as superoxide radicals and hydroxyl radicals, which contribute to oxidative damage to cellular components, including DNA, lipids, and proteins. These combined actions lead to cell cycle arrest and the induction of apoptosis (programmed cell death) in rapidly dividing cancer cells. Epirubicin is not cell-cycle specific but exhibits its most significant cytotoxic effects during the S and G2 phases of the cell cycle, rendering it effective against a broad range of neoplastic cells.